CroFab® Is Proven to Control Envenomation in Pediatric and Adult Patients
Gaining Initial Control With CroFab®
In 2 open-label trials with 42 patients with mild or moderate envenomation1,2*:
- 98% of patients administered CroFab® gained initial control
- 95% of patients showed a clinical response† 1 hour after initial control
CroFab®-treated patients gained initial control of their envenomation
Level 1 Evidence for Copperhead Envenomation3
In a placebo-controlled trial of 74 patients with copperhead envenomation published in 2017‡, CroFab® administration resulted in improved limb function vs placebo on Day 14 post envenomation. Patients treated with CroFab® achieved better functional outcomes sooner compared with placebo-treated patients (Patient-Specific Functional Scale [PSFS] score at Day 14: 8.6 vs 7.4, respectively; P=0.04).
Crofab®-treated patients demonstrated improved functioning
Patients treated with CroFab® required less opioid use at all time points, compared with placebo (up to 28 days).
CroFab®-treated patients required less opioid use
Watch Dr. Rutherfoord Rose discuss using CroFab® to treat copperhead envenomation.
Review the safety profile you can count on.
1. CroFab® [prescribing Information]. BTG International Inc; January 2018. 2. Data on file. Conshohocken, PA; BTG International Inc. 2019. 3. Gerardo CJ, Quackenbush E, Lewis B, et al. The efficacy of crotalidae polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2017;70(2):233-244. 4. Freiermuth CE, Lavonas EJ, Anderson VE, et al. Antivenom treatment is associated with fewer patients using opioids after Copperhead envenomation. West J Emerg Med. 2019;20(3):497-505.